Protection of PharmAust’s intellectual property has hit a milestone with the impending grant of a key patent relating to the use of Monepantel in conjunction with other drugs to treat cancer.

The European Patent Office has issued a Notice of Grant for the patent relating to pharmaceutical combinations comprising mTOR pathway-interfering drugs and anticancer compounds for particular use in cancer treatment.

The significance of this patent cannot be underestimated. Combination-drug therapy is widespread in cancer treatment, where the therapeutic regimen aims to minimise the possibility of drug resistance.

PharmAust (ASX:PAA) is trialling MPL and other drug combinations which interfere with the mTOR pathway as a potential way to treat cancer and neurodegenerative diseases.

The patent is expected to be published on 8 March under number EP3062790, extending the company’s existing patent coverage. PharmAust has an extensive IP portfolio that includes granted patents in Australia, the US, China, Japan, Korea, Canada and New Zealand.

mTOR pathway inhibitor

MPL is an inhibitor of the mTOR pathway, which typically regulates cell proliferation and immune cell differentiation but is also known to play an important role in tumour metabolism as well as development of diseases such as Alzheimer’s and other ageing disorders.

Inhibiting the pathway could prevent cancer growth and spread.

PharmAust is already carrying out Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs with results thus far showing that the treatment is well-tolerated in humans with preliminary evidence of anticancer activity as well as objective anticancer activity in dogs.




This article was developed in collaboration with PharmAust (ASX:PAA), a Stockhead advertiser at the time of publishing.


This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.